CHAPTER 9 Hypersensitivity Disorders Mediated by Allergen- Specific Ige Antibodies
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Aeroallergen-Induced Th2 Inflammation Endogenous And
Endogenous and Exogenous IL-6 Inhibit Aeroallergen-Induced Th2 Inflammation Jingming Wang, Robert J. Homer, Qingsheng Chen and Jack A. Elias This information is current as of September 26, 2021. J Immunol 2000; 165:4051-4061; ; doi: 10.4049/jimmunol.165.7.4051 http://www.jimmunol.org/content/165/7/4051 Downloaded from References This article cites 61 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/165/7/4051.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 26, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Endogenous and Exogenous IL-6 Inhibit Aeroallergen-Induced Th2 Inflammation1 Jingming Wang,* Robert J. Homer,† Qingsheng Chen,* and Jack A. Elias2* Chronic Th2-dominated inflammation and exaggerated IL-6 production are characteristic features of the asthmatic airway. To understand the processes that are responsible for the chronicity of this response and the role(s) of IL-6 in the regulation of airway Th2 inflammation, we compared the responses induced by OVA in sensitized wild-type mice, IL-6 deficient (؊/؊) mice, and transgenic mice in which IL-6 was overexpressed in the airway (CC10-IL-6 mice). -
Approaches for Assessing Health Risks from Complex Mixtures in Indoor Air: a Panel Overview by Carol J
Environmental Health Perspectives Vol. 95, pp. 135-143, 1991 Approaches for Assessing Health Risks from Complex Mixtures in Indoor Air: A Panel Overview by Carol J. Henry,* Lawrence Fishbein,* William J. Meggs,t Nicholas A. Ashford,' Paul A. Schulte,§ Henry Anderson,/' J. Scott Osborne,' and Daniel W. Sepkovictt Critical to a more definitive human health assessment ofthe potential health risks from exposure to complex mixtures in indoor air is the need for a more definitive clinical measure and etiology ofthe helath effects ofcomplex mixtures. This panel overview highlights six ofthe eight presentations ofthe conference panel discussion and features a number ofthe major topical areas of indoor air concern. W. G. Meggs assessed clinical research priorities with primary focus on the role ofvolatile organic chemicals in human health, recognizing the areas where definitive data are lacking. By recogniz- ing many types ofchemical sensitivity, it may be possible to design studies that can illuminate the mechanisms by which chemical exposure may cause disease. The critically important topic of multiple chemical sensitivity was discussed by N. A. Ashford, who identified four high risk groups and defined the demographics ofthese groups. P. A. Schulte address- ed the issue ofbiological markers ofsusceptibility with specific considerations ofboth methodologia and societal aspects that may be operative in the ability to detect innate or inborne differences between individuals and populations. Three case studies were reviewed. H. Anderson discussed the past and present priorities from a public health perspective, focusing on those issues dealing with exposures to environmental tobacco smoke and formaldehyde off-gassing from materials used in mobile homeconstruction. -
TITLE of STUDY Milk Allergy Is a Very Common Problem in Children. Milk
TITLE OF STUDY Milk Desensitization and Induction of Tolerance in Children Milk Allergy is a very common problem in children. Milk-induced symptoms effect up-to 20% of children, with detrimental effects on nutrition during critical periods of growth. Moreover, approximately 2-5% of children make IgE antibodies against cow’s milk, which are responsible for severe allergic reactions and anaphylaxis. Milk is the second most common food causing life-threatening anaphylaxis in North America and Europe, and the most common food to cause life- threatening symptoms world-wide. Due to the ubiquitous nature of dairy products in our diet, milk is extremely difficult to avoid. Treatment of milk allergy is currently based on strict avoidance, and patients must carry injectable adrenalin (e.g. Epipen). Our study will assess a novel and potentially life-changing therapy, by actively treating milk allergy with Oral Immunotherapy. This may allow patients to safely consume dairy products. Treatment with oral-immunotherapy has been piloted in the USA and Europe, but there is no current research into milk- immunotherapy in Canada, depriving our population of a potential cure for this very common problem. We propose to perform a well-defined clinical study, using proper control groups and immunological measures to properly understand the ideal patients and the safest and most efficacious methodologies. If successful, this study will clearly increase the margin of safety for children and young adults who suffer from life-threatening milk allergy. It can also increase the consumption of dairy products within this population, providing nutritional benefits including improved bone mineralization and growth. -
Aeroallergen Sensitization and Allergic Disease Phenotypes in Asia
REVIEW ARTICLE Asian Pacific Journal of Allergy and Immunology Aeroallergen sensitization and allergic disease phenotypes in Asia Elizabeth Huiwen Tham,1,2 Alison Joanne Lee,1,2 Hugo Van Bever1,2 Abstract Allergic diseases are on the rise in Asia. Aeroallergen exposure is a strong risk factor for sensitization, development and severity of atopic diseases, especially in the Asian paediatric population. Geographical and seasonal variations in aeroallergen sensitization are seen even within Asian countries and changes in aeroallergen sensitization patterns have been observed over time. Some possible reasons include climate change as well as rapid urbanization and improved sanitation which follow socioeconomic development. House dust mite allergy is present in up to 90% of Asian atopic patients, far exceeding that which is seen in Western populations which report prevalences of only 50% to 70%. Pollen and animal dander affect less than 10% of Asian patients as compared to 40-70% of individuals with asthma and allergic rhinitis living in the West, a burden almost equivalent to the dust mite burden in those regions. There is thus a pressing need for preventive measures to reduce dust mite sensitization in Asian children today. Keywords: Aeroallergen, Asia, allergy, house dust mites, sensitization From: Corresponding author: 1 Department of Paediatrics, Yong Loo Lin School of Medicine, National Elizabeth Huiwen Tham University of Singapore Department of Paediatrics, Yong Loo Lin School of Medicine, National 2 Khoo Teck Puat-National University -
Xolair® (Omalizumab)
Xolair® (omalizumab) When requesting Xolair® (omalizumab), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications and meet the specific coverage guidelines and applicable safety criteria for the covered indications. FDA-approved indications • Xolair® (omalizumab) is indicated for the treatment of moderate to severe persistent asthma in individuals with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids. • Xolair® (omalizumab) is indicated for the treatment of chronic idiopathic urticaria in individuals who remain symptomatic despite treatment with a histamine-1 (H1) antihistamine. Approved Off-label Compendial use • None Coverage Guidelines Moderate to Severe Persistent Asthma The individual must meet all of the following criteria for initial approval: • Diagnosis of moderate to severe persistent allergic asthma confirmed by appropriate diagnostic testing • Greater than or equal to 6 years of age • Has a positive skin test or in vitro reactivity to a perennial aeroallergen • Has inadequate control of symptoms after 3 months of consecutive treatment with the following o High-dose corticosteroid o Long-acting beta agonist or leukotriene inhibitors • Age 12 years and over: Has baseline serum total Immunoglobulin E (IgE) levels between 30 Units/mL and 700 Units/mL • Age 6 years to less than 12 years: Has baseline serum total Immunoglobulin E (IgE) levels between 30 Units/mL and up to 1300 Units/mL • Has a body weight that is 150 kg or less • Is not concurrently taking Cinqair, Nucala, or Fasenra V1.0.2019 - Effective 1/1/2019 © 2019 eviCore healthcare. -
Peptide Allergen Immunotherapy: a New Perspective in Olive-Pollen Allergy
pharmaceutics Review Peptide Allergen Immunotherapy: A New Perspective in Olive-Pollen Allergy David Calzada 1,†, Lucía Cremades-Jimeno 1,†, María López-Ramos 1 and Blanca Cárdaba 1,2,* 1 Immunology Department, IIS-Fundación Jiménez Díaz-UAM, 28040 Madrid, Spain; [email protected] (D.C.); [email protected] (L.C.-J.); [email protected] (M.L.-R.) 2 Ciber de Enfermedades Respiratorias (CIBERES), 28029 Madrid, Spain * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Allergic diseases are highly prevalent disorders, mainly in industrialized countries where they constitute a high global health problem. Allergy is defined as an immune response “shifted toward a type 2 inflammation” induced by the interaction between the antigen (allergen) and IgE antibodies bound to mast cells and basophils that induce the release of inflammatory mediators that cause the clinical symptoms. Currently, allergen-specific immunotherapy (AIT) is the only treatment able to change the course of these diseases, modifying the type 2 inflammatory response by an allergenic tolerance, where the implication of T regulatory (Treg) cells is considered essential. The pollen of the olive tree is one of the most prevalent causes of respiratory allergic diseases in Mediterranean countries, inducing mainly nasal and conjunctival symptoms, although, in areas with a high antigenic load, olive-tree pollen may cause asthma exacerbation. Classically, olive-pollen allergy treatment has been based on specific immunotherapy using whole-olive pollen extracts. Citation: Calzada, D.; Despite extracts standardization, the effectiveness of this strategy varies widely, therefore there is a Cremades-Jimeno, L.; López-Ramos, need for more effective AIT approaches. -
Monitoring of Occupational and Environmental Aeroallergens – EAACI Position Paper
POSITION PAPER Monitoring of occupational and environmental aeroallergens – EAACI Position Paper Concerted action of the EAACI IG Occupational Allergy and Aerobiology & Air Pollution M. Raulf1, J. Buters2, M. Chapman3, L. Cecchi4, F. de Blay5, G. Doekes6, W. Eduard7, D. Heederik6, M. F. Jeebhay8, S. Kespohl1,E.Krop6, G. Moscato9, G. Pala10, S. Quirce11, I. Sander1, V. Schlunssen€ 12, T. Sigsgaard12, J. Walusiak-Skorupa13, M. Wiszniewska13, I. M. Wouters6 & I. Annesi-Maesano14,15 1Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Ruhr-Universitat€ Bochum (IPA), Bochum; 2ZAUM- Center of Allergy & Environment, Helmholtz Zentrum Munchen/Technical€ Universitat€ Munchen,€ Christine Kuhne€ Center for Allergy Research and Education (CK-CARE), Member of the German Center of Lung Research (DZL), Munich, Germany; 3Indoor Biotechnologies Ltd, Cardiff, UK; 4Interdepartmental Centre of Bioclimatology, University of Florence, Allergy and Clinical Immunology Section, Azienda Sanitaria di Prato, Prato, Italy; 5Department of Chest Diseases, University Hospital Strasbourg, Strasbourg, France; 6Division of Environmental Epidemiology, Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands; 7Department of Chemical and Biological Work Environment/National Institute of Occupational Health, Institute of Medical Biology, University in Tromsø, Tromsø, Norway; 8Centre for Occupational and Environmental Health Research, School of Public Health and Family Medicine, University of Cape Town, -
Allergen Immunotherapy in Asthma; What Is New? Giovanni Passalacqua*, Anthi Rogkakou, Marcello Mincarini and Giorgio Walter Canonica
Passalacqua et al. Asthma Research and Practice (2015) 1:6 DOI 10.1186/s40733-015-0006-2 REVIEW Open Access Allergen immunotherapy in asthma; what is new? Giovanni Passalacqua*, Anthi Rogkakou, Marcello Mincarini and Giorgio Walter Canonica Abstract The use and role of allergen immunotherapy (AIT) in asthma is still a matter of debate, and no definite recommendation about this is made in guidelines, both for the subcutaneous and sublingual routes. This is essentially due to the fact that most controlled randomised trials were not specifically designed for asthma, and that objective measures of pulmonary function were only occasionally considered. Nonetheless, in many trials, favourable results in asthma (symptoms, medication usage, bronchial reactivity) were consistently reported. There are also several meta analyses in favour of AIT, although their validity is limited by a relevant methodological heterogeneity. In addition to the crude clinical effect, a disease modifying action of AIT (prevention of asthma onset and long-lasting effects) have been reported. The safety is an important aspect to consider in asthma. Fatalities were rare: in Europe no fatality was reported in the last three decades, as in the United States in the last 4 years. Based on previous surveys, and common sense, uncontrolled asthma is still recognized as the most important risk factor for severe adverse events. On the contrary, there is no evidence that AIT can worsen or induce asthma. According to the available evidence, AIT can be safely used as add-on treatment when asthma is associated with rhinitis (a frequent condition), provided that asthma is adequately controlled by pharmacotherapy. -
Allergen Immunotherapy
Allergen Immunotherapy Introduction This Factsheet is a summary of the various forms of immunotherapy. We focus primarily on food allergies and insect sting allergy (which are the core work of the Anaphylaxis Campaign) but also give some basic information on treatments for allergic rhinitis (hay fever). Some reference is made to treatments for eczema and asthma. Throughout this Factsheet you will see brief medical references given in brackets. Full references are provided at the end. What is allergen immunotherapy? Allergy occurs when a person’s immune system reacts in an inappropriate or exaggerated way to a food or substance that, in the majority of people, causes no symptoms. A food or substance that causes an allergic reaction is called an allergen. Allergen immunotherapy, previously known as desensitisation, is a medical treatment for allergies. The idea is that the patient’s immune system can be ‘trained’ to tolerate the allergen and therefore not cause allergic symptoms. Allergen immunotherapy for hay fever and asthma has been shown to have benefits for many years after stopping the treatment, where treatment has been ongoing for at least 3-5 years. This has not yet been shown for food allergy to date. Research is also underway to assess whether immunotherapy can potentially reduce the risk of the development of asthma and new allergies. There is some evidence that pollen immunotherapy for hay fever reduces the subsequent risk of developing asthma and that therapy to treat one allergy reduces the subsequent risk of developing reactions to other allergens (Des Roches A, 1997; Purello D, 2001; Panjo GB, 2001). -
Respiratory Food Allergy
Respiratory Food Allergy Elham Hossny, MD, PhD, FAAAAI Head, Pediatric Allergy and Immunology Unit, Children’s Hospital, Ain Shams University Conflicts of Interest Nothing to disclose • There is clinical evidence that food allergy plays a role in the pathogenesis of respiratory disorders • This seems to be more common in infants and young children than adults CONTENT • Causative food allergens • Respiratory manifestations of food allergy • Indications of screening for food allergy • Key notes and unmet needs Causative Food Allergens Class I food allergens: Milk, egg, seafood, peanut, tree nuts, wheat, and soy (most common) Class II food allergens: Fruits and vegetables (food-pollen syndrome) • Cow's milk is one of the first foreign proteins ingested by infants and is one of the most common and potent food allergens. • Contamination of probiotic preparations with milk allergens can cause anaphylaxis in children with cow's milk allergy. Causative food allergens (Cont’d) The presence of egg allergy in infancy especially when coexisting with eczema increases the likelihood of respiratory allergy and aeroallergen sensitization in early childhood. Tariq SM, et al. Pediatr Allergy Immunol 2000;11:162-7. Food Pollen Syndrome = Oral Allergy Syndrome • Cross-reactive allergens between certain foods and airborne pollens • The most famous cross reacting allergen is profillin Birch pollen – almonds – apples – apricots – carrots – celery – cherries – kiwifruit – parsley – peaches – pears – peppers – plums – potatoes – prunes Food Pollen Syndrome (Cont’d) Grass pollen – Melons – Tomatoes – Oranges Ragweed pollen – Banana – Cantaloupe – Watermelon – Cucumber – Zucchini 0-5 6-10 11-15 Pollen food syndrome amongst children with seasonal allergic rhinitis attending allergy clinic Ludman S, et al. -
PDF Full-Text
50 Z. Caliskaner et al. Original Article Skin test positivity to aeroallergens in the patients with chronic urticaria without allergic respiratory disease Z. Caliskaner1, S. Ozturk1, M. Turan2, M. Karaayvaz1 Gülhane Military Medical Academy and Medical Faculty, 1 Department Allergy and 2 Department of Hydroclimatology and Medical Ecology, Ankara, Türkiye (www.gata.edu.tr/dahilibilimler/allerji/index.htm) Summary. The etiology of chronic urticaria and angioedema remains uncertain in most of the patients. There are several agents and factors including medications, foods and food additives, infections, contactants, inhalants, physical factors and autoimmunity that implicated in provoking urticaria symptoms. In addition, the possible role of house dust mites has been considered in a few reports. We investigated skin test positivity to house dust mites and other inhalants in 259 patients with chronic idiopathic urticaria and angioedema but without allergic rhinitis and/or asthma. Results were compared with both 300 healthy controls and 300 atopic patients. Immediate cutaneous reactivity to one or more allergens was detected in 71 patients in the study group (27.4 %). The most common allergens were house dust mites (24.7 %). Skin prick test sensitivity to other inhalant allergens including pollens, molds and cockroach were 7.7 %, 0.4 % and 0.8 %, respectively. In the healthy control group 7 % of patients were found as atopic with respect to skin prick test results. The most common allergens in healthy controls were pollens (6 %), and house dust mites (4.7 %). In atopic control group, pollens and mites are also the most common allergens detected in skin prick test (62 % and 50.3 %, respectively). -
European Standards and North American Practice Parameters for Skin Prick Testing Panels in Allergic Rhinitis and Asthma
Romanian Journal of Rhinology, Vol. 5, No. 17, January-March 2015 DOI: 10.1515/rjr-2015-0002 LITERATURE REVIEW European standards and North American practice parameters for skin prick testing panels in allergic rhinitis and asthma Florin-Dan Popescu Department of Allergology, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania ABSTRACT According to the Global Allergy and Asthma European Network (GA²LEN), a pan-European skin prick test panel for the diag- nosis of allergic rhinitis and asthma includes 18 aeroallergen extracts, supplemented if necessary for regional or for particular patient needs, while the Allergen Subcommittee and Immunotherapy Committee of the American Academy of Allergy, Asthma and Immunology (AAAAI) selected 36 major clinically relevant aeroallergens for North America. KEYWORDS: aeroallergen extracts, skin prick tests, allergic rhinitis and asthma INTRODUCTION PARAMETERS FOR SKIN PRICK TESTING PANELS Skin prick testing is an important reliable method to diagnose IgE-mediated allergic rhinitis, rhinocon- The aeroallergen extracts included in the Euro- junctivitis and asthma. This widely used in vivo assess- pean standards and North American practice param- ment, indicated, performed and interpreted by al- eters skin prick panels are of plant, fungal and ani- lergy practitioners, is minimally invasive, has immedi- mal origins, as described below1-8. ately available and reproducible results, and provides Aeroallergen extracts of animal origin included in evidence for aeroallergen sensitization. Skin prick these standards belong to Arthropoda phylum, Astig- tests are highly specific and sensitive for the diagnosis mata order (house dust mites from the Pyroglyphidae of respiratory allergies. The positive predictive value family), Blattodea order (Ectobiidea family from the to diagnose allergic rhinitis increases to 97-99% if al- Insecta class), and Carnivora order pet animals (Felidae lergy skin prick testing is utilized1,2.